Molecular Pharmacology Program
The Alex Kentsis Lab
We study the biology of cancers that affect children and young adults ranging from embryonal tumors in infants, leukemias and brain tumors in children, and sarcomas in young adults. Scientists in our group use inter-disciplinary experimental tools as they work to understand the fundamental causes of cancer and to develop definitive therapies for their control. Detailed information about our research is available at http://alexkentsis.net.
Jubierre L, Rodriguez Fos, Planas-Felix, Lewis, Cameron, Demarest, Nabila, Zhao, Bergin, Reed, Yamada, Socci, Hayes, Rabadan, Torrents, Kruer, Toth, Kentsis A. A transposase-derived gene required for human brain development. bioRxiv.
Bigot Y, Yamada M, Mueller H, Morell V, Alves S, Lecomte T, Kentsis A. Analysis of DNA transposition by DNA transposases in human cells. bioRxiv.
Kazansky Y, Cameron D, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Kuwahara Y, Qu R, de Stanchina E, Dela Cruz F, Kung A, Gounder M, Kentsis A. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. bioRxiv.
Kwok N, Aretz Z, Takao S, Ser Z, Cifani P, Kentsis A. Integrative proteogenomics using ProteomeGenerator2. bioRxiv.
Keller R, Yamada M, Cameron D, Suzuki H, Sanghrajka R, Vaynshteyn J, Gerwin J, Maura F, Hooper W, Shah M, Robine N, Demarest P, Bayin SN, Jubierre L, Reed C, Taylor MD, Joyner AL, Raju PG, Kentsis A. Childhood cancer mutagenesis caused by a domesticated DNA transposase. bioRxiv.
Alex Kentsis, MD, PhD
- Cancer biologist and pediatric oncologist Alex Kentsis leads research in the functional proteomics and molecular pharmacology of refractory childhood cancers.
- MD, Mount Sinai School of Medicine
- PhD, New York University
- [email protected]
- Email Address
- Office Phone
- View physician profile
- Physician profile
- Louise and Allston Boyer Award for Clinical Research
- Terry Ann Krulwich Physician-Scientist Alumni Award
- Pershing Square Sohn Prize
- Leukemia & Lymphoma Society Scholar Award
- Josie Robertson Investigator (2013-2018)
- St. Baldrick’s Robert J. Arceci Innovation Award
- Elected Member of American Society for Clinical Investigation
- Society for Pediatric Research Young Investigator Award
- Rita Allen Foundation Scholar Award
- Damon Runyon Cancer Research Foundation Clinical Investigator Award
- American Society of Hematology Scholar Award
- Burroughs Wellcome Fund Career Award for Medical Scientists
- Pediatric Hematology-Oncology Fellowship, Dana-Farber Cancer Institute
- Residency in Pediatrics, Boston Children’s Hospital, Harvard Medical School
- MD, PhD, Mount Sinai School of Medicine and New York University
- AB, SM, University of Chicago
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Lab Head Email
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alex Kentsis discloses the following relationships and financial interests:
Provision of Services
Day One Biopharmaceuticals, Inc.
Provision of Services
Provision of Services
Rgenta Therapeutics Inc.
Ownership / Equity Interests; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].